Cara Therapeutics | CARA - Ebitda


Cara Therapeutics reported $-2.39M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Cipla INR 9.55B 3B Mar/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
J&J USD 7.19B 2.32B Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pacira USD 40.24M 1.53M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
RedHill Biopharma USD 2.69M 108.46M Jun/2023
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024